Section II: changing “anti-temperature” to “anti-pyritic”; 1. analgesic agents with opide containing 2. analgesic agent without opide containing; Section III. The antiallergenic drugs and drugs for hypersensitivity should be changed to the antiallergenic and anti- hypersensitivity agents. Section IV. The anti-toxic: 4.1 specific anti-toxic; 4.2.non- specific anti -toxic agents
Pharmaceutical Preparations ; Drugs, Essential

Study aimed to introduce some principles for selecting the essential drugs in the list including assurance of effective and safe treatment, suitability with ability of patient’s cost and health insurance budget and using of the drug list (modern medicine and traditional medicine and regulation of use).
Pharmaceutical Preparations ; Drugs, Essential

The list of essential drug of VN, 1998 as follows: 1. Anaesthesia; 2. Non - steroidal anti inflammatory and antigouty drugs; 3. Anti-allergy and hyper- sensitivity; 4. Anti-toxicity; 5. Anti-epilepsy; 6. Anti-microbial and helminthicide; 7. Anti-migraine; 8. Anti-cancer and immunosuppression; 9. Anti- Parkinson; 10. Blood system drugs; 11. Blood-products-blood replacement; 12. Cardiovascular drugs; 13. External medicine; 14. Hormone; Endocrine and contraceptive drugs; 15. Microbicide; 16. Diuretic; 17. Gastrointestinal track; 18. Drugs for diagnostics; 19. Immunological drug; 20. Myodilator; 21. Drugs in ear, nose-throat; 22. Oxytocic, antihemorrhagic after delivery and anti premature born; 23. Dialysis solutions; 24. Anti- psychological disorder; 25. Drug for respiratory tract; 26. Solutions for electrolyte and water balance and acid-base balance; 27. Vitamin and mineral elements
Pharmaceutical Preparations ; Drugs, Essential

The domestic medicinal plants and brand name originated from domestic medicinal plants should be added in the list of essential drug. The pharmacological term should be united in all documents. The correct drug name will contribute to safe and rational use of the drugs.
Pharmaceutical Preparations ; Drugs, Essential

Based on the survey of the essential drug management at 26 communal health stations (CHSs) in Ba BÓ district, B¾c C¹n province, the authors showed that all the health stations have applied correctly the rule for managing almost of listed drugs. Type and quantity of the essential drugs at the communal health stations have been insufficient to meet the people’s needs. There is only about 20% of drugs that listed in the third essential drug list of ViÖt Nam Ministry of Health). Rate of infectious drugs is highest. Amount of drug that supplied by CHSs occupies only 49% of total drug supply. Only 11.53% of CHSs have the pharmacist. Only 11% of health workers were received training in pharmaceutical management. 93% of the health workers have trouble in drug prescribing and advising because the lack of knowledge on drug classes or new drugs. The rate of using herbal to treat patients at the commune stations remained to be low (7.7%). The authors called for some measures to improve the essential drug use and management at communal level
Drugs, Essential ; Residence Characteristics

Introduce nation policy about essential drugs (TTY) in background of nation economic recently. Provide essential drugs ability for people include: produce ability drugs in the fourth essential drugs list, which was promulgated at 28/7/1999 consist of drug list, traditional medicine, providing supplement essential drugs ability from foreign companies. A few proposes and comments of author.
Drugs, Essential ; Pharmaceutical Preparations ; Research Subjects

BACKGROUNDAt the present time, the government is considering to establish the independent financing system for essential medicines (EMs). However, it is still in the exploration phase. The objectives of this study were to calculate and estimate financing amount of EMs in China in 2014 and to provide data evidence for establishing financing mechanism of EMs.

METHODSTwo approaches were adopted in this study. First, we used a retrospective research to estimate the cost of EMs in China in 2014. We identified all the 520 drugs listed in the latest national EMs list (2012) and calculated the total sales amount of these drugs in 2014. The other approach included the steps that first selecting the 109 most common diseases in China, then identifying the EMs used to treat them, and finally estimating the total cost of these drugs.

RESULTSThe results of the two methods, which showed the estimated financing amounts of EMs in China in 2014, were 17,776.44 million USD and 19,094.09 million USD, respectively.

CONCLUSIONSComparing these two results, we concluded that the annual budget needed to provide for the EMs in China would be about 20 billion USD. Our study also indicated that the irrational drug use continued to plague the health system with intravenous fluids and antibiotics being the typical examples, as observed in other studies.

This study took the 2020 edition of Chinese Pharmacopoeia(ChP) and the 2018 edition of National Essential Drug List(NEDL) for children as research carriers to systematically analyze the current situation of and problems in the use of Chinese patent medicine for children(CPMC) in China. In view of the problems of imprecise dosage, incomplete safety information, and lack of sui-table varieties, dosage form and specification of CPMC in China, development strategy of CPMC in the future was proposed. It is reco-mmended to carry out systematic post-marketing revaluation studies of CPMC, encourage the development of new varieties or new dosa-ge forms suitable for children, advocate the continuous promotion of real-world studies on children, and expand the information on the use of CPMC with real-world data, so as to lay the foundation for post-marketing revaluation of CPMC and guide the rational use of clini-cal medicines. This study was expected to build a positive policy ecosystem to ensure the supply of CPMC, and promote the high-quality development of CPMC.
Child ; Humans ; Nonprescription Drugs ; Medicine, Chinese Traditional ; Ecosystem ; Drugs, Essential ; China ; Drugs, Chinese Herbal

At present, most of Chinese patent medicines have problems, such as weak scientific basis, unclear clinical value evaluation, etc., which lead to the lack of sufficient evidence for the entry into the essential medicine list, medical insurance catalog and other important health resource allocation tools. This has a negative impact on the development of traditional Chinese medicine. It is urgent to establish a comprehensive evaluation methodology system of Chinese patent medicine in China. There are at least three reasons including producing evidence for clinical rational use scientifically, developing an objective and transparent selecting strategy, eventuating and highlighting its clinical value. The process and method of health technology assessment(HTA) can provide reference for the establishment of comprehensive evaluation method of Chinese patent medicine. However, HTA is rarely carried out in the field of traditional Chinese medicine. The latest domestic and international research showed that HTA combined with multi-criteria decision analysis(MCDA) can increase the transparency of decision-making and improve the quality of decision-making. The combined two formed the EVIDEM framework, which is conducive to drug selection and its clinical use. In this paper, the EVIDEM framework was introduced to establish the methodology framework of the comprehensive clinical evaluation system of Chinese patent medicine. A preliminary research idea has been put forward. In the future, we can establish a set of comprehensive clinical evaluation methods for Chinese patent medicine in cooperation with relevant national drug decision-making departments and management departments. It is believed that such cooperation could promote the full implementation of the re-evaluation for Chinese patent medicine.
China ; Drugs, Essential ; Medicine, Chinese Traditional ; Nonprescription Drugs ; Technology Assessment, Biomedical

This study evaluated the clinical effectiveness of Ruyi Zhenbao Pills in the treatment of osteoarthritis, aiming to clarify its clinical advantages and promote rational drug use and related policy transformation. Following the relevant standards in Guidelines for the Comprehensive Evaluation of Drugs in Clinical Practice and Technical Specifications for the Clinical Comprehensive Evaluation of Chinese Patent Medicine, comprehensive research and related data on Ruyi Zhenbao Pills in the treatment of osteoarthritis were collected in the dimensions of safety, effectiveness, economy, innovation, suitability, accessibility, and traditional Chinese medicine(TCM) cha-racteristics(referred to as the "6+1" dimensions). Through evidence-based medicine, questionnaire surveys, health technology assessment, pharmacoeconomic evaluation, and other methods, a multi-criteria decision analysis(MCDA) model and CSC v2.0 software were used to comprehensively evaluate the clinical value of Ruyi Zhenbao Pills. Spontaneous reporting system data on adverse reactions and literature data indicate that the adverse reactions of Ruyi Zhenbao Pills are mostly general adverse reactions, with no reports of se-rious adverse reactions. The known risks are small, and its safety is rated as class A. It has been shown to effectively relieve joint pain and restore joint function in the treatment of osteoarthritis. However, more high-quality, large-sample randomized controlled trials are needed to further validate its effectiveness, which is rated as class B. There is evidence supporting its economic viability, and its economic is rated as class B. It demonstrates good clinical innovation, innovative enterprise service system, and industrial innovation, and innovation is rated as class A. Medical professionals and patients have a favorable perception of the suitability of Ruyi Zhenbao Pills, and further improvement can be made in terms of convenience of administration and promotion to facilitate rational drug use by healthcare professionals and patients. Suitability is rated as class B. The drug has a favorable price level, availability, and affordability, and accessibility is rated as class A. Ruyi Zhenbao Pills are a classic Tibetan medicinal prescription with excellent TCM theoretical characteristics. However, further research is needed on its use in human studies. TCM characteristics are rated as class B. Based on the evaluation results of the "6+1" dimensions, the comprehensive clinical evaluation is rated as grade B. Ruyi Zhenbao Pills have good clinical value in the treatment of osteoarthritis, and it is recommended to undergo the necessary procedures for conditional transformation into a policy for the management of essential clinical drugs.
Humans ; Medicine, Chinese Traditional ; Reference Standards ; Nonprescription Drugs ; Drugs, Essential ; Osteoarthritis/drug therapy* ; Drugs, Chinese Herbal/adverse effects*